InSite unveils DuraSite 2 ophthalmic drug delivery system
DuraSite 2 is expected to increase the tissue penetration for topically delivered ocular drugs and improve dosing convenience, according to the company. The data published by the company
Vertex has signed a definitive agreement to purchase Crinetics Pharmaceuticals in a transaction valued at nearly $10bn, or $8.8bn net of estimated cash acquired.